Biocytogen and Acepodia Sign Option and License Agreement for Bispecific and Dual-Payload ADC Programs
I'm PortAI, I can summarize articles.
Biocytogen Pharmaceuticals and Acepodia have signed an option and license agreement for bispecific antibody-drug conjugate (BsADC) programs, including dual-payload variants. Acepodia can obtain an exclusive worldwide license for two BsADC programs from Biocytogen. The agreement includes an upfront option fee, potential exercise fees, milestone payments, and royalties on future sales, though financial terms remain undisclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments